Catalent will begin the first phase of a planned $100 million expansion at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities to support the growing European market demand for biologics manufacture and supply.   The initial phase of the expansion will include the installation of two 2,000-liter single-use bioreactors within new, purpose-built manufacturing suites and associated investments to support early-phase clinical development and late-stage and com...